- EQS-Adhoc: Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annual General Meeting
- EQS-Adhoc: Cosmo Pharmaceuticals announces a change in its board of directors
- EQS-Adhoc: Cosmo announces the start of trading of its shares on XETRA
- EQS-Adhoc: Cosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy
- EQS-Adhoc: Cosmo Full-Year Report 2020: Cosmo returns to operating profit
Cosmo Pharmaceuticals NV (COPN:SWX) closed at 89.10, -8.43% below its 52-week high of 97.30, set on Aug 31, 2020.
71.10Oct 29 202097.30Aug 31 2020
Markit short selling activity
|Market cap||1.34bn CHF|
|EPS (TTM)||-0.5975 |
Data delayed at least 15 minutes, as of Jun 18 2021 16:31 BST.